VERACYTE, INC. Cost, Direct Material
VERACYTE, INC. (VCYT) reported Cost, Direct Material of $446.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostDirectMaterial · last filed 2020-02-25
- VERACYTE, INC. cost, direct material for fiscal 2019 was $446.00K.
- VERACYTE, INC. cost, direct material for fiscal 2018 was $0.00.
- VERACYTE, INC. cost, direct material for fiscal 2017 was $0.00.
| Period end | Cost, Direct Material 12 month |
|---|---|
| 2019-12-31 | $446.00K 10-K · filed 2020-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |